Roche, Genentech plunk down $60M upfront to partner with Chinese pharma on PROTAC-based prostate cancer drug – Endpoints News

0
25
Roche, Genentech plunk down $60M upfront to partner with Chinese pharma on PROTAC-based prostate cancer drug – Endpoints News


Roche and Genen­tech are al­ways on the hunt for deals, and on Thurs­day they found their newest part­ner.

The pair will team up with the Chi­nese phar­ma com­pa­ny Jem­incare to push for­ward a new pro­gram for prostate can­cer, the com­pa­nies an­nounced. Roche is pony­ing up $60 mil­lion up­front to get its hands on the can­di­date and promis­ing up to $590 mil­lion in biobucks, plus roy­al­ties, down the line.

In re­turn, Genen­tech will get a world­wide li­cense to de­vel­op the pro­gram, known as JMKX002992, and bring it to mar­ket.

Jem­incare ini­tial­ly de­vel­oped the pro­gram based on PRO­TAC tech­nol­o­gy, ac­cord­ing to its web­site. It’s an oral, small mol­e­cule de­grad­er of the an­dro­gen re­cep­tor, a pop­u­lar tar­get in prostate can­cer with a long R&D his­to­ry. Sev­er­al ap­proved prostate can­cer drugs, such as Pfiz­er’s Xtan­di and J&J’s Er­lea­da, are de­signed to in­hib­it the re­cep­tor.

But Jem­incare went with the degra­da­tion route, hop­ing to treat pa­tients whose can­cers de­vel­oped re­sis­tances to oth­er ther­a­pies. JMKX002992 is one of Jem­incare’s four on­col­o­gy pro­grams cur­rent­ly in the pipeline, on top of ex­per­i­men­tal re­nal can­cer, non-small cell lung can­cer and FIC drugs.

The Chi­nese phar­ma is al­so work­ing in oth­er dis­ease ar­eas, de­vel­op­ing pro­grams for kid­ney dis­ease, res­pi­ra­to­ry dis­ease and pain. Thus far, Jem­incare has clinched five drug ap­provals in Chi­na, in­clud­ing an­oth­er prostate can­cer drug in An­droblok.

Ad­di­tion­al­ly, Jem­incare is part­nered with Ori­on to de­vel­op a se­lec­tive NaV 1.8 block­er to treat acute and chron­ic pain.

Thurs­day’s move comes on the heels of an­oth­er deal for Roche and Genen­tech. Ear­li­er this month, the pair signed on to a Phase II pro­gram from Kiniksa, pay­ing $80 mil­lion up­front and an­oth­er $20 mil­lion in near-term pay­ments. If every­thing works out in that deal, Kiniksa could earn up to $600 mil­lion in mile­stones.



Source link